1Department of Anatomical Pathology, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
2Human Cancer Research Center-Indonesian Medical Education and Research Institute, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
3Faculty of Medicine, Universitas Muhammadiyah Palembang, Palembang, Indonesia
4Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin General Hospital, Bandung, Indonesia
5Department of Otorhinolaryngology, Head and Neck Surgery, Harapan Kita National Women and Children Health Center, Jakarta, Indonesia
6Department of Anatomical Pathology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
7Department of Anatomical Pathology, Faculty of Medicine, Andalas University, Padang, Indonesia
8Department of Anatomical Pathology, Faculty of Medicine, Universitas Brawijaya/RSUD dr. Saiful Anwar, Malang, Indonesia
9Department of Anatomical Pathology, Faculty of Medicine and Health Science, Universitas Jambi, Jambi, Indonesia
10Department of Anatomical Pathology, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin General Hospital, Bandung, Indonesia
11Department of Anatomical Pathology, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia
12Department of Anatomical Pathology, Faculty of Medicine, University of Lampung, Lampung, Indonesia
13Department of Anatomical Pathology, Faculty of Medicine, University of Sriwijaya, Palembang, Indonesia
14Department of Anatomical Pathology, Labuha Hospital, South Halmahera, Indonesia
15Department of Anatomical Pathology, Faculty of Medicine, Universitas Udayana, Prof. Dr. I.G.N.G. Ngoerah Hospital, Denpasar, Indonesia
16Department of Anatomical Pathology, Faculty of Medicine, Universitas Airlangga/Dr Soetomo Academic Hospital, Surabaya, Indonesia
17Department of Anatomical Pathology, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada/UGM Academic Hospital, Yogyakarta, Indonesia
18Department of Anatomical Pathology, Dr. Ben Mboi Hospital, Kupang, Indonesia
19Kanujoso Djatiwibowo Hospital, Balikpapan, Indonesia
20Department of Pathology and Thyroid Disease Center, Izumi City General Hospital, Izumi, Japan
© The Korean Society of Pathologists/The Korean Society for Cytopathology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Ethics Statement
This study was approved by the Ethics Committee of the Faculty of Medicine Universitas Indonesia – Dr. Cipto Mangunkusumo Hospital, under protocol number KET-620/UN2.F1/ETIK/PPM.00.02.2023. The requirement for informed consent was waived by the committee under protocol number ND-0313/UN2.F1.DEPT.27/PPM.00.02/2023.
Availability of Data and Material
The datasets generated or analyzed during the study are available from the corresponding author on reasonable request.
Code Availability
Not applicable.
Author Contributions
Conceptualization: ASH, MFH, KK. Methodology: ASH, AHA, DK, MM, KK. Software: AHA. Validation: ASH and MFH. Formal analysis: MM, DK. Investigation: ASH, KK. Resources: ASH. Data curation: AA, DPR, FQ, HA, HI, HC, IW, KM, MT, NMM, NK, NA, PA, YPS, ASH. Writing— original draft preparation: ASH, AHA, DK, MM. Writing—review and editing: AA, DPR, FQ, HA, HI, HC, IW, KM, MT, NMM, NK, NA, PA, YPS, ASH, KK. Visualization: ASH, AHA. Project administration: MM. Funding acquisition: ASH. All authors have read and agreed to the published version of the manuscript.
Conflicts of Interest
K.K., a contributing editor of the Journal of Pathology and Translational Medicine, was not involved in the editorial evaluation or decision to publish this article. All remaining authors have declared no conflicts of interest.
Funding Statement
The authors would like to thank Universitas Indonesia for funding this research through a PUTI grant with contract number NKB-615/UN2.RST/HKP.05.00/2024.
Variable | Round | Mean kappa | 95% CI | p-value |
---|---|---|---|---|
Three-point score system | First | 0.21 | –0.57 to 0.01 | .052 |
Second | 0.49 | |||
Eight-point score system | First | 0.10 | –0.32 to –0.16 | .001 |
Second | 0.34 |
Nuclear feature | Score |
---|---|
Nuclear size and shape | |
Nuclear enlargement | 0: Absent or only slightly expressed |
Nuclear crowding/overlapping | 1: Present or well developed |
Nuclear elongation | |
Membrane irregularities | |
Irregular membrane contour | 0: Absent or only slightly expressed |
Nuclear grooves | 1: Present or well developed |
Nuclear pseudoinclusions | |
Chromatin characteristics | |
Chromatin clearing | 0: Absent or only slightly expressed |
Margination of chromatin to membrane | 1: Present or well developed |
Glassy nuclei | |
Total score | 0–1: Not diagnostic for PTC nuclei |
2–3: Diagnostic for PTC nuclei |
Nuclear feature | Score |
---|---|
Nuclear enlargement | 0: Absent |
1: Present in < 10% of tumor cells | |
2: Present in ≥ 10% of tumor cells | |
Nuclear crowding/overlapping | 0: Absent |
1: Present in < 10% of tumor cells | |
2: Present in ≥ 10% of tumor cells | |
Nuclear elongation | 0: Absent |
1: Present in < 10% of tumor cells | |
2: Present in ≥ 10% of tumor cells | |
Irregular membrane contour | 0: Absent |
1: Present in < 10% of tumor cells | |
2: Present in ≥ 10% of tumor cells | |
Nuclear grooves | 0: Absent |
1: Present in < 10% of tumor cells | |
2: Present in ≥ 10% of tumor cells | |
Nuclear pseudoinclusions | 0: Absent |
1: Present | |
Chromatin clearing | 0: Absent |
1: Present in < 10% of tumor cells | |
2: Present in ≥ 10% of tumor cells | |
PTC-nuclear features distribution | 0: Focal |
1: Diffuse | |
Total score | 0–14 |
Characteristic | No. (%) |
---|---|
Age (yr) | |
Mean ± SD | 45.7 ± 5.1 |
31–40 | 1 (6.7) |
41–50 | 12 (80.0) |
51–60 | 2 (13.3) |
Sex | |
Male | 3 (20.0) |
Female | 12 (80.0) |
Years of practice | |
Mean ± SD | 10.3 ± 3.9 |
0–5 | 2 (13.3) |
6–10 | 7 (46.7) |
11–20 | 6 (40.0) |
Teaching hospital | |
Yes | 12 (80.0) |
No | 3 (20.0) |
Pathology consultant | |
Yes | 9 (60.0) |
No | 6 (40.0) |
Thyroid case/yr | |
Median (min–max) | 110 (21–1,200) |
IQR (25–75) | 50–217 |
Study pathology abroad | |
Yes | 5 (33.3) |
No | 10 (66.7) |
Length of study (mo) | |
Mean ± SD | 8.2 ± 9.9 |
1–6 | 3 (60.0) |
7–12 | 1 (20.0) |
13–18 | 0 |
19–24 | 1 (20.0) |
Topic/field of the study | |
Bone marrow pathology | 1 (20.0) |
Lymphoma | 1 (20.0) |
Molecular pathology | 2 (40.0) |
Vascular | 1 (20.0) |
Section entire tumor capsule | |
Yes | 7 (46.7) |
No | 8 (53.3) |
Blocks sample in a 4 cm thyroid nodule | |
< 5 blocks | 4 (50.0) |
5–8 blocks | 4 (50.0) |
> 8 blocks | 0 |
Diagnose NIFTP in pathology practice | |
Yes | 15 (100) |
No | 0 |
Receive clinical and radiological information in routine practice | |
Yes | 6 (40.0) |
Sometimes | 8 (53.3) |
No | 1 (6.7) |
First time using digital pathology | |
Yes | 4 (26.7) |
No | 11 (73.3) |
Nuclear feature | Round one |
Round two |
||||||
---|---|---|---|---|---|---|---|---|
Kappa | p-value | 95% CI | Strength | Kappa | p-value | 95% CI | Strength | |
Three-point scoring system | ||||||||
Nuclear size and shape | 0.14 | < .001 | 0.14 to 0.14 | Slight | 0.30 | < .001 | 0.30 to 0.30 | Fair |
Membrane irregularities | 0.28 | < .001 | 0.28 to 0.28 | Fair | 0.57 | < .001 | 0.57 to 0.58 | Moderate |
Chromatin features | 0.21 | < .001 | 0.20 to 0.21 | Fair | 0.59 | < .001 | 0.59 to 0.59 | Moderate |
Total score | 0.17 | < .001 | 0.17 to 0.17 | Slight | 0.39 | < .001 | 0.39 to 0.39 | Fair |
Eight-point scoring system | ||||||||
Nuclear enlargement | 0.09 | .001 | 0.08 to 0.09 | Slight | 0.36 | < .001 | 0.36 to 0.36 | Fair |
Nuclear crowding/overlapping | 0.01 | .987 | –0.01 to 0.01 | Slight | 0.38 | < .001 | 0.38 to 0.38 | Fair |
Nuclear elongation | 0.20 | < .001 | 0.20 to 0.20 | Slight | 0.37 | < .001 | 0.37 to 0.38 | Fair |
Irregular membrane contour | 0.13 | < .001 | 0.13 to 0.13 | Slight | 0.48 | < .001 | 0.48 to 0.48 | Moderate |
Nuclear grooves | 0.07 | .005 | 0.07 to 0.08 | Slight | 0.19 | < .001 | 0.19 to 0.20 | Slight |
Nuclear pseudo-inclusion | 0.24 | < .001 | 0.24 to 0.24 | Fair | 0.35 | < .001 | 0.35 to 0.36 | Fair |
PTC-nuclear features distribution | –0.02 | .481 | –0.02 to –0.02 | Poor | 0.23 | < .001 | 0.23 to 0.23 | Fair |
Chromatin clearing | 0.12 | < .001 | 0.12 to 0.12 | Slight | 0.38 | < .001 | 0.38 to 0.39 | Fair |
Total score | –0.01 | .611 | –0.01 to –0.01 | Poor | 0.05 | < .001 | 0.04 to 0.05 | Slight |
Variable | Round | Mean kappa | 95% CI | p-value |
---|---|---|---|---|
Three-point score system | First | 0.21 | –0.57 to 0.01 | .052 |
Second | 0.49 | |||
Eight-point score system | First | 0.10 | –0.32 to –0.16 | .001 |
Second | 0.34 |
Molecular type |
Vascular invasion |
Capsular invasion |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Kappa | p-value | 95% CI | Strength | Kappa | p-value | 95% CI | Strength | Kappa | p-value | 95% CI | Strength | |
All pathologists | 0.74 | < .001 | 0.74–0.74 | Substantial | 0.35 | < .001 | 0.35–0.36 | Fair | 0.27 | < .001 | 0.29–0.27 | Fair |
Endocrine experts | 0.84 | < .001 | 0.84–0.85 | Almost perfect | 0.21 | < .001 | 0.21–0.22 | Fair | 0.26 | < .001 | 0.26–0.27 | Fair |
Non-endocrine experts | 0.69 | < .001 | 0.68–0.69 | Substantial | 0.53 | < .001 | 0.52–0.52 | Moderate | 0.25 | < .001 | 0.25–0.26 | Fair |
PTC, papillary thyroid carcinoma.
PTC, papillary thyroid carcinoma.
SD, standard deviation; IQR, interquartile range; NIFTP, non-invasive follicular thyroid neoplasm with papillary-like nuclear features.
CI, confidence interval; PTC, papillary thyroid carcinoma.
CI, confidence interval.
CI, confidence interval.